Cannabis Laws in Switzerland

Legal Status at a Glance

Category	Status	Details
Personal Possession (up to 10g)	Decriminalized	Art. 19b BetmG; fixed fine of 100 CHF; no criminal record; applies to adults 18+
Possession (above 10g)	Criminal Offence	Art. 19 BetmG; up to 3 years imprisonment or fine; supply presumption applied
CBD Cannabis (<1% THC)	Fully Legal	Switzerland 1% threshold (vs EU 0.3%); sold in shops, kiosks, pharmacies, supermarkets
Pilot Program Cannabis	Legal (Residents Only)	Basel, Zurich, Bern, Geneva; registered Swiss residents only; scientific research framework
Medical Cannabis	Legal	Swissmedic exceptional authorization; physician prescription; pharmacies dispense; insurance coverage varies
Trafficking / Sales	Illegal	Art. 19 BetmG; up to 20 years for organized trafficking; actively prosecuted by cantonal police
Driving Under Influence	Criminal Offence	SVG Art. 91; detectable THC or impairment; fine, license suspension, possible prison; zero tolerance

Current Legal Framework

Switzerland's cannabis framework operates under the federal Narcotics Act (Betäubungsmittelgesetz, BetmG), originally enacted in 1951 and significantly revised in 2008 and 2013. The 2013 revision introduced Article 19b, which decriminalized personal possession of up to 10 grams of cannabis for adult users with a fixed administrative fine of 100 CHF (approximately 110 EUR). This was a pragmatic reform that avoided the political controversy of full decriminalization while reducing the burden on courts and police from minor possession cases. No criminal record results from a 100 CHF fine under Article 19b. Above 10 grams, Article 19 applies with penalties of up to 3 years imprisonment or a significant financial penalty. Qualified cases — trafficking, organized crime, large quantities — carry up to 20 years under Article 19 paragraph 2.

Switzerland most distinctive cannabis policy development is its 1% THC threshold for CBD cannabis, established in 2016 through an interpretation of the Narcotics Act's exemption for hemp. The EU standard for industrial hemp is 0.3% THC; Switzerland 1% limit is more than three times more permissive and places Switzerland in a unique position within European cannabis markets. Cannabis products with THC below 1% are classified as hemp products exempt from the Narcotics Act and can be legally produced, sold, and consumed. This created an immediate boom in Swiss CBD cannabis products — cannabis flowers with THC between 0.3% and 1% are functionally indistinguishable from regular cannabis in appearance, smell, and much of their effect profile, making Swiss CBD shops among the most sophisticated cannabis retail environments in Europe without operating outside the law.

The most significant development in Swiss cannabis policy is the 2021 amendment to the Narcotics Act (Article 8a) authorizing scientific pilot studies for regulated cannabis access. These studies allow adult Swiss residents to participate in time-limited programs where they can legally purchase cannabis of defined quality and potency from licensed dispensaries, pharmacies, or social clubs, with researchers tracking health outcomes, usage patterns, and social consequences. The first pilot study launched in Basel in early 2023 through pharmacies, with Zurich following with a cannabis social club model and Bern with a pharmacy-based distribution. Geneva and other cities began their own pilot programs through 2024. By 2025, approximately 4,000 to 5,000 Swiss residents were enrolled in pilot programs across multiple cities. These pilots are designed to generate the scientific evidence base for a potential future national regulated market — Switzerland is explicitly using a research methodology similar to Uruguay's pragmatic model.

Swiss cannabis policy is notable for its cantonal variability within the federal framework. Cantons have discretion over enforcement priorities, and the urban cantons of Basel-City, Zurich, Geneva, and Bern have historically applied the personal use decriminalization rules more consistently than some rural cantons. Cantonal police forces set their own enforcement priorities within the federal law. The pilot programs are also canton-specific — participation is city-by-city rather than nationally available. This federal structure means the cannabis experience varies meaningfully across Switzerland, with the major German-speaking and French-speaking cities generally more permissive in practice than smaller towns and rural areas.

Penalties and Enforcement

Offense	Quantity	Penalty	Enforcement Reality
Personal Possession	Up to 10g	100 CHF fixed fine	Consistent enforcement across cantons; fine paid on spot or by post; no arrest, no record
Possession Above Limit	Above 10g	Up to 3 years or fine	Criminal file opened; courts typically issue conditional sentences for first offenders; suspended sentences common
Trafficking (Basic)	Any supply	Up to 3 years (Art. 19)	Active enforcement; cantonal police use undercover operations in Zurich, Basel, Geneva
Organized Trafficking	Organized / large	Up to 20 years (Art. 19 para. 2)	Fedpol and cantonal cooperation; major trafficking networks prosecuted; cross-border coordination
CBD Cannabis (<1% THC)	Any amount	Legal – no penalty	Sold openly; occasional confusion at borders with other EU/EEA countries where 0.3% is the threshold
Driving Under Influence	Any detectable THC	Fine + license suspension; possible prison	Zero tolerance; saliva and blood testing; impairment without detectable THC also prosecuted

Medical Cannabis Program

Switzerland's medical cannabis framework operates through Swissmedic, the Swiss Agency for Therapeutic Products, which has the authority to grant exceptional authorizations for substances not covered by regular therapeutic product approvals. Prior to 2022, physicians wishing to prescribe cannabis-based medicines for patients who had not responded to conventional treatments needed to apply individually to Swissmedic for each patient — a burdensome process that limited access. In 2022, Swissmedic streamlined the exceptional authorization process, significantly reducing administrative barriers and enabling more physicians to prescribe cannabis medicines efficiently.

Under the current system, licensed physicians in any specialty can prescribe cannabis-based medicines with Swissmedic authorization for patients with a wide range of conditions including chronic pain, multiple sclerosis spasticity, chemotherapy side effects, treatment-resistant epilepsy, palliative care, and psychiatric conditions unresponsive to conventional treatment. Authorized prescriptions are dispensed through licensed pharmacies. Several cannabis-based medicines are available including Sativex (nabiximols), Epidyolex (cannabidiol), and pharmacy-compounded cannabis flower and oil preparations using Swissmedic-authorized active pharmaceutical ingredients from licensed producers. By 2025, an estimated 12,000 to 18,000 Swiss patients had active medical cannabis prescriptions, with the number growing rapidly following the 2022 streamlining.

Switzerland insurance system (Krankenkasse/Caisse-maladie under the compulsory basic insurance framework) does not cover medical cannabis under standard basic insurance policies. Supplementary insurance (Zusatzversicherung/assurance complémentaire) may cover some cannabis treatments. This creates a significant affordability barrier — licensed medical cannabis products cost between 150 and 400 CHF per month depending on treatment, making sustained treatment challenging for lower-income patients. Patient advocacy organizations have been lobbying for basic insurance coverage, and the pilot program research is expected to generate cost-effectiveness data that could support a future reimbursement decision.

Industry and Market Data

Switzerland cannabis industry is defined by the extraordinary success of its CBD sector. The 1% THC threshold created an immediate business opportunity after 2016, and Swiss CBD cannabis production and retail expanded rapidly. By 2020, Switzerland had approximately 500 to 700 licensed hemp and CBD cultivation operations, several hundred CBD retail shops, and significant online CBD commerce. Swiss CBD flowers — sold as "legal cannabis" — became significant export products to neighboring EU countries where they occupy a grey area between hemp and cannabis regulation. Several Swiss cities including Basel, Zurich, and Geneva developed dense clusters of CBD shops, some in premium retail locations with sophisticated branding comparable to legal dispensaries in North American markets.

The illicit cannabis market in Switzerland is estimated to involve approximately 300,000 to 500,000 regular users, with an annual market value of 600 million to 1 billion CHF. The high incomes in Swiss cities drive relatively high cannabis prices compared to neighboring countries — illicit cannabis typically sells for 10 to 20 CHF per gram in Zurich and Geneva, significantly above German or Dutch street prices. This price premium supports the black market's persistence despite the legal CBD alternative. The pilot programs are partly designed to test whether a legal regulated market can compete with the illicit market on price, quality assurance, and convenience — early pilot program pricing has been set at approximately 8 to 12 CHF per gram to ensure competitive positioning.

Switzerland cannabis industry is increasingly integrated with European pharmaceutical supply chains. Several Swiss companies produce GMP-certified cannabis medicines for domestic use and export. Switzerland's sophisticated pharmaceutical manufacturing infrastructure and Swissmedic's regulatory reliability make it an attractive base for international cannabis pharmaceutical companies. The pilot program infrastructure — which includes licensed cultivation, processing, quality testing, and distribution operations — may provide the foundation for a commercial regulated market if Swiss voters and parliament decide to pursue full legalization following the pilot evidence period.

Cannabis Culture and History

Switzerland cannabis culture is shaped by the country's multilingual, multicultural character and its high-income urban population. Cannabis use is most prevalent in the German-speaking cities of Zurich, Basel, and Bern and in the French-speaking cities of Geneva and Lausanne, reflecting European norms across both linguistic communities. Hemp cultivation has deep historical roots in Switzerland — hemp fiber was important to Swiss agriculture from the medieval period through the 18th century, and Swiss hemp rope and textiles were valued export products. Modern cannabis use developed alongside European cultural trends from the 1960s onward, with Zurich and Geneva developing significant cannabis-using subcultures among students, artists, and counterculture communities.

Zurich's Letzigrund area and the "Needle Park" (Platzspitz) became internationally notorious in the late 1980s and early 1990s for open heroin use, driving Switzerland to pioneer harm reduction approaches — needle exchanges, heroin-assisted treatment, drug checking — that influenced global policy. Cannabis was a less acute public health concern than heroin in this period, and its cultural normalization continued steadily. By the 2000s, cannabis use in Swiss cities was normalized enough that leading figures in politics, business, and culture openly discussed their cannabis histories, reducing the stigma that persisted in more conservative European countries.

The Basel cannabis culture deserves specific attention given Basel's role as Switzerland's first pilot program city. Basel-City is Switzerland's smallest canton by area but one of its most cosmopolitan — a dense urban environment at the junction of Switzerland, Germany, and France, with a high concentration of pharmaceutical industry workers, art world professionals (home of Art Basel), and international residents. The cannabis culture in Basel reflects this cosmopolitanism: tolerant, sophisticated, with significant demand for quality-controlled products. The Basel pilot, which uses licensed pharmacies as distribution points, has been cited as a potential model for how pharmaceutical-grade retail cannabis could be integrated into existing healthcare infrastructure in a way that appeals to health-conscious, quality-focused urban consumers.

Traveler Guide

Do's

• Explore Switzerland's outstanding CBD cannabis shops — the 1% THC threshold means Swiss legal CBD is genuinely different from what's available in EU countries; Zurich, Basel, Geneva, and Bern all have excellent CBD retail
• Keep possession within the 10g decriminalized limit — above this is criminal; within it is just a 100 CHF fine with no record
• Understand the CBD threshold difference — Swiss legal CBD at 0.8% to 0.99% THC is more potent than typical 0.2% to 0.3% EU CBD products; calibrate your experience accordingly
• Use cannabis discreetly in outdoor spaces — Swiss urban parks are tolerant environments; Zurich's Platzspitz, Basel's Rhine banks, and Geneva's lakefront are low-enforcement outdoor spaces
• Note that CBD from Switzerland may cause issues at EU borders — EU border controls may not recognize the 1% Swiss standard; take only what you'll consume in Switzerland
• Engage with the pilot program from an observer perspective — if you know Swiss residents enrolled, understanding their experience provides insight into one of the world's most interesting cannabis policy experiments

Don'ts

• Never attempt to join the pilot programs as a tourist — they require Swiss residency registration; attempting to misrepresent your status is fraud
• Never drive with cannabis in your system — Swiss traffic law is zero tolerance and cantonal police conduct roadside testing actively
• Never carry Swiss CBD cannabis into EU/EEA countries — the EU's 0.3% THC threshold means Swiss CBD between 0.3% and 1% is potentially illegal across most EU borders
• Do not exceed the 10g decriminalized limit — the step from administrative fine to criminal prosecution is sharp; 10g is the hard line
• Never purchase on the illicit market — Swiss black market cannabis carries the same criminal risks as anywhere; given the legal CBD option, there's no reason to engage with illicit sellers
• Do not assume cantonal rules are identical — while federal law is uniform, enforcement varies; urban cantons are more permissive than rural ones in practice

Frequently Asked Questions